The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

banner

InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases

13-May-2015 | Source : AG-IP News | Visits : 4558
VANCOUVER, BC - InMed Pharmaceuticals Inc. announced in a press release that it has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO") relating to the treatment of eye diseases.
 
Dr. Sazzad Hossain, CSO of InMed, commented, "We are pleased that our R & D efforts have culminated in the filing of a patent application within this large area of unmet medical needs. We have continued to build our expertise in the ocular disease area and believe the application that we have filed with the USPTO allows the Company to pursue a strategic IP strategy around the ocular therapy space including Glaucoma and other ocular diseases."
 
Mr. Craig Schneider, CEO of InMed, commented, "The filing of this patent application supplements our existing intellectual property portfolio and we plan to continue to file additional patent applications covering our technologies and novel therapies that will drive our long-term shareholder value."
 
A provisional patent application is a legal document which establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals that may want to file for a patent with similar claims after the filing date of our provisional application. 

InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis-based therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary platform technology, product pipeline, and accelerated development pathway are the fundamental value drivers of the Company.
 
share



Related Articles